Kotak Nifty Alpha 50 ETF Share Target 2024, 2025 To 2039
|
Kotak Nifty Alpha 50 ETF |
|||
|
Price: ₹54.22 | ||
| 52 Week Low: ₹41.31 52 Week High: ₹60.91 |
|||
| Market Capital: N/A | |||
| Healthcare -> Biotechnology | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Kotak Nifty Alpha 50 ETF Share Price Target For 2024
- 1.1.1: Kotak Nifty Alpha 50 ETF Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Kotak Nifty Alpha 50 ETF Share Price Target For 2025
- 1.2.1: Kotak Nifty Alpha 50 ETF Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Kotak Nifty Alpha 50 ETF Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Kotak Nifty Alpha 50 ETF Brief Company Overview
To predict the Kotak Nifty Alpha 50 ETF's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Kotak Nifty Alpha 50 ETF Share Price Target For 2024
The line chart displays the monthly closing prices of Kotak Nifty Alpha 50 ETF with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Kotak Nifty Alpha 50 ETF shares in 2024, see the table below.
Kotak Nifty Alpha 50 ETF Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 56.05 (+3.37%) | Price Action: 19 Sep 2024 Low |
| 2024 Target 2 | 55.49 (+2.34%) | Price Action: 21 Oct 2024 Low |
| 2024 Target 1 | 54.88 (+1.21%) | Price Action: 23 Dec 2024 High |
| Current Price | 54.22 | Kotak Nifty Alpha 50 ETF's share price as of 26 Dec 2024 |
| Stop Loss 1 | 53.92 (-0.56%) | Price Action: 28 Oct 2024 High |
| Stop Loss 2 | 53.36 (-1.59%) | Price Action: 08 Nov 2024 Low |
| Stop Loss 3 | 52.79 (-2.64%) | Price Action: 13 Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: Kotak Nifty Alpha 50 ETF is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹54.51 serves as the nearest technical reference point.
Historical Returns: 3-month: -6.76% | 6-month: +0.3% | 1-year: NA
Kotak Nifty Alpha 50 ETF Share Price Target For 2025
The line chart displays the monthly closing prices of Kotak Nifty Alpha 50 ETF with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Kotak Nifty Alpha 50 ETF shares in 2025, see the table below.
Kotak Nifty Alpha 50 ETF Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 68.89 (+27.05%) | Price Action: Chart |
| 2025 Target 2 | 67.61 (+24.69%) | Price Action: Chart |
| 2025 Target 1 | 66.94 (+23.45%) | Fibonacci Extension Level 64.90% |
| Current Price | 54.22 | Kotak Nifty Alpha 50 ETF's share price as of 26 Dec 2024 |
| Stop Loss 1 | 51.3 (-5.39%) | Price Action: Oct 2024 Low |
| Stop Loss 2 | 50.73 (-6.44%) | Price Action: 14 Nov 2024 Low |
| Stop Loss 3 | 50.1 (-7.6%) | Price Action: 31 May 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Kotak Nifty Alpha 50 ETF is currently trading at 65.9% of its 52-week range (₹41.31 - ₹60.91).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: NA | 3-year: NA | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Kotak Nifty Alpha 50 ETF Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹54.22 | ||
| 2024 | ₹60.20 | +11.02% | ₹61.10 |
| 2025 | ₹72.21 | +19.95% | ₹73.29 |
| 2026 | ₹86.82 | +20.23% | ₹88.12 |
| 2027 | ₹100.28 | +15.5% | ₹101.78 |
| 2028 | ₹113.64 | +13.32% | ₹115.34 |
| 2029 | ₹127.01 | +11.76% | ₹128.92 |
| 2030 | ₹137.79 | +8.48% | ₹139.86 |
| 2031 | ₹153.54 | +11.43% | ₹155.84 |
| 2032 | ₹167.09 | +8.82% | ₹169.60 |
| 2033 | ₹180.45 | +7.99% | ₹183.16 |
| 2034 | ₹193.82 | +7.4% | ₹196.73 |
| 2035 | ₹203.38 | +4.93% | ₹206.43 |
| 2036 | ₹220.27 | +8.3% | ₹223.57 |
| 2037 | ₹233.90 | +6.18% | ₹237.41 |
| 2038 | ₹247.27 | +5.71% | ₹250.98 |
| 2039 | ₹259.51 | +4.95% | ₹263.40 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Kotak Nifty Alpha 50 ETF Brief Company Overview
Company Overview of Pharnext SA Pharnext SA is a clinical-stage biopharmaceutical company established in 2007 and headquartered in Paris, France. The company is committed to developing innovative therapies for neurodegenerative diseases that have high unmet medical...
needs. Key Products and Services PXT3003: A fixed-dose combination therapy for Charcot-Marie-tooth disease type 1A. PXT864: A treatment for amyotrophic lateral sclerosis. Reputation and Market Presence Pharnext SA has a strong reputation in the industry for its innovative approach to drug development. The company's diverse product range and commitment to addressing unmet medical needs make it a valuable player in the neurodegenerative disease market.Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
